DE Burlo Group Inc. Has $17.71 Million Stock Holdings in Novo Nordisk A/S (NYSE:NVO)

DE Burlo Group Inc. decreased its position in shares of Novo Nordisk A/S (NYSE:NVO) by 13.8% in the 3rd quarter, Holdings Channel reports. The firm owned 148,730 shares of the company’s stock after selling 23,850 shares during the quarter. Novo Nordisk A/S accounts for about 2.2% of DE Burlo Group Inc.’s portfolio, making the stock its 20th largest holding. DE Burlo Group Inc.’s holdings in Novo Nordisk A/S were worth $17,709,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently added to or reduced their stakes in the company. Massachusetts Financial Services Co. MA raised its holdings in Novo Nordisk A/S by 2.8% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 79,660 shares of the company’s stock worth $9,485,000 after purchasing an additional 2,166 shares during the last quarter. LPL Financial LLC increased its stake in shares of Novo Nordisk A/S by 3.6% in the 3rd quarter. LPL Financial LLC now owns 1,362,782 shares of the company’s stock valued at $162,266,000 after acquiring an additional 47,496 shares in the last quarter. Citizens Financial Group Inc. RI increased its stake in shares of Novo Nordisk A/S by 1.9% in the 3rd quarter. Citizens Financial Group Inc. RI now owns 14,301 shares of the company’s stock valued at $1,703,000 after acquiring an additional 263 shares in the last quarter. EagleClaw Capital Managment LLC increased its stake in shares of Novo Nordisk A/S by 4.1% in the 3rd quarter. EagleClaw Capital Managment LLC now owns 65,850 shares of the company’s stock valued at $7,841,000 after acquiring an additional 2,575 shares in the last quarter. Finally, First Horizon Advisors Inc. increased its stake in shares of Novo Nordisk A/S by 55.5% in the 3rd quarter. First Horizon Advisors Inc. now owns 7,238 shares of the company’s stock valued at $862,000 after acquiring an additional 2,582 shares in the last quarter. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Trading Up 2.6 %

Novo Nordisk A/S stock opened at $105.30 on Thursday. Novo Nordisk A/S has a one year low of $94.73 and a one year high of $148.15. The stock has a market cap of $472.51 billion, a PE ratio of 34.08, a price-to-earnings-growth ratio of 1.32 and a beta of 0.42. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.75 and a current ratio of 0.94. The stock has a 50-day moving average of $116.80 and a two-hundred day moving average of $129.11.

Wall Street Analyst Weigh In

A number of analysts have commented on NVO shares. Cantor Fitzgerald restated an “overweight” rating and set a $160.00 price target on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. BMO Capital Markets decreased their price objective on Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating for the company in a report on Thursday, October 17th. Finally, StockNews.com raised Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a research report on Friday, November 1st. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $144.50.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.